Key result
Pharmacist-led interventions significantly decreased systolic blood pressure by 7.12 mmHg compared with usual care (P=0.020) in patients with chronic kidney disease and hypertension.
Why the study?
Only about 50% of patients with high blood pressure and chronic kidney disease comorbidity achieve blood pressure control.
Do pharmacist-led interventions reduce mean BP and improve BP control in hypertensive patients with CKD compared with usual care?
RCT (n=147)
Double-blind
randomized
Yes
Do pharmacist-led interventions reduce mean BP and improve BP control in hypertensive patients with CKD compared with usual care?
Effect estimate: 7.12 mmHg decrease
p-value: p=.020
Pharmacist-led interventions significantly reduce systolic blood pressure in hypertensive patients with chronic kidney disease compared to usual care.
Supports pharmacist-led hypertension care in CKD; extends team-based BP management evidence to this high-risk population.
Introduction Only about 50% of patients with high blood pressure (BP) and chronic kidney disease (CKD) comorbidity have their BP controlled. Objectives The objectives of the study were to determine whether pharmacist‐led interventions reduce mean BP and improve BP control in hypertensive patients with CKD compared with usual care. Methods This 12‐month prospective, double‐blind, randomized, controlled trial was conducted at two major hospitals in Nigeria. Seventy‐four participants were randomized to the usual care arm serving as the control and 73 participants were randomized to the intervention arm. The intervention arm received home BP monitors, and pharmacological and nonpharmacological (education and training on self‐management of CKD and hypertension, and text messages) interventions. Results Baseline characteristics were similar between the intervention (n = 73) and usual care (n = 74) participants. However, significantly more females were in the intervention arm compared with the usual care arm (71.2% vs 52.7%; P = .021). Compared with the usual care arm, systolic BP (SBP) significantly decreased by 7.12 mmHg from baseline ( P = .020) in the intervention arm. Higher proportions of patients gained BP control from baseline to 6 months (27.4% vs 13.5%, P = .095), and from baseline to 12 months (20.5% vs 8.1%, P = .096) in the intervention arm than the usual care. There were no statistical differences, but clinical differences were observed. Conclusion This trial demonstrates that including a clinical pharmacist in a team care setting can improve BP reduction and control in patients with CKD and hypertension. Trial registration ClinicalTrials.gov NCT05254392.
No takes yet. Share an insight, caveat, or question.
Okoro et al. (2022) conducted an RCT in Chronic kidney disease and hypertension (n=147). Pharmacist-led interventions vs. Usual care was evaluated on Systolic BP (SBP) decrease from baseline (7.12 mmHg decrease, p=.020). Pharmacist-led interventions significantly decreased systolic blood pressure by 7.12 mmHg compared with usual care (P=0.020) in patients with chronic kidney disease and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: